DZ Bank reaffirmed their sell rating on shares of Stada Arzneimittel (OTCMKTS:STDAF) in a research report report published on Tuesday.

Separately, Nord/LB restated a sell rating on shares of Stada Arzneimittel in a research note on Tuesday, January 2nd.

Shares of Stada Arzneimittel (OTCMKTS:STDAF) opened at $104.04 on Tuesday. The firm has a market capitalization of $6,742.29, a P/E ratio of 63.44 and a beta of -0.51. Stada Arzneimittel has a 52 week low of $57.93 and a 52 week high of $108.40.

WARNING: This article was first reported by Daily Political and is the property of of Daily Political. If you are viewing this article on another domain, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this article can be accessed at

Stada Arzneimittel Company Profile

STADA Arzneimittel Aktiengesellschaft engages in the development and marketing of active pharmaceutical ingredients for the health care and pharmaceutical markets worldwide. It operates through two segments, Generics and Branded Products. The Generics segment provides various generic active ingredients, including Tilidine naloxone for pain; Atorvastatin for elevated cholesterol levels; Pantoprazole for stomach ulcer/reflux; Diclofenac for pain/inflammation; and Enalapril for high blood pressure indications.

Receive News & Ratings for Stada Arzneimittel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stada Arzneimittel and related companies with's FREE daily email newsletter.